我国自主知识产权的重组人干扰素α1b在儿科的创新研究与临床实践(上)  

Innovative research and clinical application of recombinant human interferon alpha1b in pediatrics(Volume Ⅰ)

作　　者：尚云晓[1] 张国成[2] Shang Yunxiao;Zhang Guocheng(Shengjing Hospital of China Medical University,Pediatric Respiratory Medicine,Shenyang 110004,China;Children′s Hospital,China Armed Police Service School of Medicine,Tianjing 300163,China)

机构地区：[1]中国医科大学附属盛京医院小儿呼吸内科,沈阳110004 [2]中国武警后勤学院医学院儿童医院,天津300163

出　　处：《国际儿科学杂志》2019年第7期461-464,共4页International Journal of Pediatrics

摘　　要：重组人干扰素α1b(IFN-α1b)是我国第一个国际独创的基因工程新药.IFN-α1b作为人体天然抗病毒的主要干扰素亚型,具有高度的安全性和广谱抗病毒作用,在儿科抗病毒领域具有广阔的应用前景.我国在全球率先开展了IFN-α1b治疗小儿呼吸道合胞病毒(RSV)肺炎的临床研究,完成了治疗毛细支气管炎、手足口病、疱疹性咽峡炎、病毒性腹泻等多中心临床研究,并形成了符合我国国情的临床专家共识和指南.该文就IFN-α1b的创新研究进行总结,并提出儿科临床应用中的常见问题以及应用潜力.Recombinant human interferonα1b(IFN-α1b)is the first internationally unique novel genetic engineering medicine in China.As a major interferon subtype with natural antiviral activity,IFN-α1b has high safety and broad-spectrum antiviral effect,so it has broad application prospects in the treatment of viral diseases.Chinese pediatric doctors have taken the lead globally in conducting clinical research of IFN-α1b in the treatment of respiratory syncytial virus(RSV)pneumonia、bronchiolitis、hand-foot-mouth disease,herpetic angina、viral diarrhea,etc.A series of clinical guidance and expert consensus have been published which are in line with China′s national conditions.This article summarizes the innovative research of IFN-α1b and proposes common issues and potential application in pediatric clinical applications.

关 键 词：干扰素Α1B 儿童 病毒 创新 

分 类 号：R72[医药卫生—儿科]